Paul Conrad joins Aeta Therapeutics as chief business and financial officer

Boston, USA-based biotech Aera Therapeutics, which is harnessing next-generation enabling delivery technologies and precision payloads to unlock the full potential of genetic medicines, today announced the appointment of Paul Conrad as chief business and financial officer.

Dr Conrad brings more than 30 years of biopharma experience and expertise spanning R&D, strategy and operations, business and corporate development, alliance management, and finance.
“We are excited to welcome Paul to the Aera team,” said Akin Akinc, chief executive of Aera. “Paul is a seasoned biopharmaceutical executive, and his leadership will be key as we continue to build the company, advance our programs toward the clinic, and develop enabling delivery technologies to expand the application and impact of genetic medicines,” he added.

Commenting on his appointment, Dr Conrad said: “With a clear focus on next-generation delivery technologies, Aera is well-positioned to impact the landscape of genetic medicines by broadening their application across many patient populations and disease areas. I am excited to be a part of Aera’s exceptional team and look forward to contributing to the next chapter of growth for the company.”